UnitedHealth Group Incorporated (UNH): 'Medicare Fraud Is Prison,' Warns Jim Cramer
UnitedHealth Group Incorporated (NYSE:UNH) is the largest healthcare benefits provider in America. It is also one of the worst-performing stocks in 2025 as the shares have lost 40% year-to-date. UnitedHealth Group Incorporated (NYSE:UNH)'s shares sank by a massive 27.3% in April after the firm stunned investors by missing analyst estimates for its latest quarter. Cramer's recent remarks about the firm discussed media reports of impropriety and pointed out that UnitedHealth Group Incorporated (NYSE:UNH) wouldn't be buying shares if they were true. However, this time, he had a much darker tone:
'[On a WSJ report that UNH deploys doctors and nurses to gather diagnoses that bolster its payments with UNH responding that it welcomes reviews] Well I'm glad they welcome it but I do want to caution them, and I think I happen to like this CEO very much, but Medicare fraud is prison. It's not, hey listen we'll slap UNH on the wrist. It's prison. And it's probably the most I think easily, the crimes are easily followed and the judgement is swift. The reason why people are so focused on this is that it's not a fine.'
Previously, the CNBC host discussed UnitedHealth Group Incorporated (NYSE:UNH) in detail:
'The third worst performer was, wow, UnitedHealth Group, suddenly very troubled managed care company that used to be the ultimate darling in the group. It's down 38% in the first half. UnitedHealth's troubles are very well documented. I'm not even talking about the assassination last December, as terrible as that was. The real trouble started in April when the company reported a weak quarter, dragged down by high utilization rates, meaning people are getting much more healthcare than UNH… needs to pay for.
A senior healthcare professional giving advice to a patient in a clinic.
What's starting to become clear is that the company made some major missteps with its underwriting, especially with Medicare Advantage plans for seniors. They're far from the only one in the industry with this problem, but UNH might be the hardest hit. This is the largest player in the Medicare Advantage space with the most extensive data, and they really should have been able to avoid these mistakes. They almost always have, but clearly, they didn't.
The company made a change in the top mid-May with CEO Andrew Witty stepping down for personal reasons. Turning around UNH is now the job of Stephen Hemsley, whom I really like. He was previously CEO from 2006 to 2017. And there's some nascent optimism that he can get this business back on track, but I don't necessarily think this will happen quickly. If you're inclined to bet on a UNH comeback, I suggest that you take it slowly because you got all the time in the world. You actually might even want to wait to see the next quarter, which could be what we call a clearing event for the negatives.'
While we acknowledge the potential of UNH as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the .
READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.
Disclosure: None. This article is originally published at Insider Monkey.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
23 minutes ago
- Yahoo
This Teen Built a Game on Roblox -- Then Sold It for Millions
Teen developers are striking gold on Roblox (NYSE:RBLX), and investors are quietly pouring in behind the scenes. A 19-year-old who built Blue Lock: Rivalsan anime-inspired soccer gamesold it for over $3 million just months after launch. At its peak, the title hit more than 1 million concurrent players and was generating roughly $5 million per month for Roblox. The buyer? Do Big Studios, a firm that's been actively snapping up hit titles across the platform, including Grow a Garden, which broke records in June with 21 million simultaneous playerssurpassing Fortnite. Warning! GuruFocus has detected 6 Warning Signs with RBLX. What's fueling this surge in deals is a structural shift in Roblox's ecosystem. A December platform update quietly made it easier for developers to transfer ownership of their gamessomething that used to violate Roblox's terms. That's opened the floodgates. Voldex, another acquisitive player, bought Brookhaven RP in February in a deal CEO Alex Singer described as bigger than Embracer Group's acquisition of Welcome to Bloxburg, which had been reported at around $100 million. Most of these deals are brokered on Discord. Many sellers remain anonymous. But behind the avatars, there's real moneyand increasing interest from capital providers like Raine Group and Shamrock Capital. Roblox's creator economy is now attracting serious financial attention. The platform is on track to pay out over $1 billion to developers this year, with the top ten creators earning $36 million each over the last 12 months. Valuations for games typically range from 112 months of revenue, depending on how stable the player base looks. Voldex has even inked partnerships with the NFL to rebrand games like Ultimate Football, extending their shelf life. Roblox isn't actively participating in these secondary market transactions, but the trajectory is clear: this could be the early innings of a new asset class where digital gamesespecially those born in teenage bedroomscommand multi-million-dollar exits. This article first appeared on GuruFocus.
Yahoo
24 minutes ago
- Yahoo
Prediction: This Stock Could Join Nvidia, Amazon, Alphabet, Microsoft, and Apple in the $2 Trillion Club By 2035
Visa, a leading financial services company, is still some ways away from a market cap of $1 trillion. The company's significant growth prospects should lead to superior returns during the next 10 years. 10 stocks we like better than Visa › In 2018, Apple became the first publicly traded company to have a $1 trillion market cap. Since then, several more have joined it at that level and some of them have even exceeded the $2 trillion mark. Today, that exclusive club comprises Nvidia, Microsoft, and Apple -- all of which are actually above $3 trillion -- as well as Amazon and Alphabet. Though payment network giant Visa (NYSE: V) hasn't even cracked the $1 trillion valuation ceiling yet -- its market cap is $680 billion as of July 11 -- I think it could join the $2 trillion club by 2035. The financial services powerhouse would need a compound annual growth rate of 11.3% during the next decade to hit that milestone. That would be no easy feat, but here's why the company could pull it off. What happens when you swipe (or tap) a credit or debit card at a point-of-sale system? Transactions of this kind are typically processed in seconds, but what goes on behind the scenes is fairly complex. Visa is at the center of it all, helping merchants connect with issuing banks and, effectively, request the data that shows whether a consumer has the money or available credit to cover the transaction. If they do, the transaction is accepted; otherwise, it is rejected. Every time a transaction is routed through its payment network, Visa pockets a small percentage of the total. According to some data, in the U.S. last year, there were an average of 1,781 credit card transactions per second, about 107,000 per minute, more than 6 million per hour, and almost 154 million per day. Of course, Visa isn't the only company in this industry, but it is the largest -- and the scale of credit and debit card usage in the U.S. should give investors an idea of the company's potential. There are nearly 5 billion cards in circulation connected to the Visa network, and during the 12 months ended March 31, it supported about 316 billion transactions and $16.1 trillion in payment volume. The company's dominance in the payments segment translates into excellent financial results. Its revenue, earnings, and free cash flow have all grown at healthy clips during the past decade. Meanwhile, it has maintained gross margins of about 80% and net margins in the vicinity of 50%. For a company of its size, that's outstanding. Visa can operate with such strong margins because it has already set up its nearly ubiquitous global payment network. Additional transactions don't meaningfully increase its cost of goods sold. In short, Visa has an excellent business that has performed exceptionally well in the past. That's no guarantee of future success, but there are good reasons to expect Visa to continue along the same path. From its fiscal 2014 through its fiscal 2024, Visa's revenue grew at a compound annual rate of almost 11%, going from $12.7 billion to $35.9 billion. It's net income measured on a GAAP (generally accepted accounting principles) basis increased at a compound annual rate of 13.8%, going from $5.4 billion to $19.7 billion. The long-term trend away from cash transactions and toward digital ones helped drive these results, but Visa still has ample room for growth. In the next decade, it could perform similarly well as it captures more of the significant share of payment volume that is still handled via cash and checks. The company's biggest competitor, Mastercard, notes that there are still about $12.5 trillion worth of cash and check transactions made annually worldwide. That's before we point out that Visa will also benefit from the increasing use of e-commerce, an area where cash and checks are hardly viable options for most transactions. That should provide Visa with ample growth fuel through the next decade and beyond. True, competition from Mastercard is a risk, as are potential economic troubles that would lead to lower consumer spending activity. However, these challenges hardly change Visa's prospects. The company can perform well despite stiff competition thanks to its powerful network effect. And while macroeconomic headwinds could sap Visa's financial results, its business is built to survive such conditions and continue thriving. Visa is well-positioned to deliver the long-term growth it needs during the next decade to become a $2 trillion company by 2035. Long-term investors should seriously consider purchasing the company's shares and holding them for the long haul. Before you buy stock in Visa, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Visa wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $671,477!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,010,880!* Now, it's worth noting Stock Advisor's total average return is 1,047% — a market-crushing outperformance compared to 180% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of July 7, 2025 Suzanne Frey, an executive at Alphabet, is a member of The Motley Fool's board of directors. John Mackey, former CEO of Whole Foods Market, an Amazon subsidiary, is a member of The Motley Fool's board of directors. Prosper Junior Bakiny has positions in Amazon, Mastercard, and Nvidia. The Motley Fool has positions in and recommends Alphabet, Amazon, Apple, Mastercard, Microsoft, Nvidia, and Visa. The Motley Fool recommends the following options: long January 2026 $395 calls on Microsoft and short January 2026 $405 calls on Microsoft. The Motley Fool has a disclosure policy. Prediction: This Stock Could Join Nvidia, Amazon, Alphabet, Microsoft, and Apple in the $2 Trillion Club By 2035 was originally published by The Motley Fool 登入存取你的投資組合
Yahoo
26 minutes ago
- Yahoo
Market Surges Amid Rising Liver Disease and Cancer Prevalence
The global ascites market is experiencing significant growth, driven by the rising prevalence of liver diseases, cancers, and other risk factors like alcohol consumption and hepatitis infections. Key advancements in diagnostic technologies, such as ultrasound and CT scans, are enhancing early detection and treatment options. Despite growth, challenges like high treatment costs and potential side effects hinder market expansion, particularly in developing regions. Leading companies, including Ocelot Bio and Regeneron Pharmaceuticals, are innovating to improve treatment efficacy. With increasing demand in emerging markets and an aging population, the ascites market is set for sustained growth. Dublin, July 14, 2025 (GLOBE NEWSWIRE) -- The "Ascites Market - A Global and Regional Analysis: Focus on Regional and Country Analysis - Analysis and Forecast, 2025-2035" report has been added to ascites market is witnessing substantial growth, driven by a range of key factors. One of the primary drivers for the ascites market is the rising prevalence of liver diseases, particularly cirrhosis, as well as various forms of cancer, such as liver, ovarian, and pancreatic cancer. As these diseases are among the leading causes of ascites, their increasing incidence globally is driving the demand for diagnostic tools and treatment options. The global rise in lifestyle diseases, alcohol consumption, and hepatitis infections has contributed to this increase, which in turn propels the growth of the ascites market. As the ascites market continues to evolve, several emerging trends are expected to significantly influence its future trajectory. The aging global population is another significant factor driving the ascites market. Older adults are more prone to liver diseases, heart failure, and cancer, all of which are major risk factors for ascites. As the number of elderly individuals increases, the prevalence of ascites is expected to rise, further driving the demand for effective treatments and management strategies. Leading players in the global ascites market, such as Ocelot Bio, Regeneron Pharmaceuticals, and BioVie Inc., are continuously focusing on several strategies to maintain their competitive edge and drive growth. These strategies include continuous technological innovation, such as the development of more advanced and efficient treatment options, mapping systems, and imaging technologies. These companies aim to enhance the safety and efficacy of ascites treatment competitive landscape of the global ascites market is diverse, with numerous players across different regions offering a wide range of products. Regional players and local manufacturers are expected to play an important role in the market's growth, especially as demand increases in emerging markets such as Asia-Pacific and Latin America. As consumer preferences shift towards more discreet, comfortable, and affordable solutions, the ascites market will continue to evolve, fostering new opportunities for both established and emerging the development and improvement of diagnostic technologies, including imaging techniques like ultrasound, CT scans, and the use of paracentesis for fluid analysis, are major drivers for the ascites market. Early detection and accurate diagnosis allow for timely intervention, improving treatment outcomes. The availability of non-invasive and highly sensitive diagnostic tests increases the likelihood of diagnosing ascites in its early stages, expanding the demand for related treatment and management the positive growth trajectory, several challenges continue to impact the global ascites market. One of the primary challenges is the high cost of treatments, particularly for advanced interventions such as liver transplants, chemotherapy, and some novel drug therapies. These costs can be a significant barrier to access, especially in developing regions where healthcare infrastructure may be limited, and insurance coverage for expensive treatments may not be available. This high cost can restrict the market growth, as many patients may not be able to afford the necessary side effects and complications of treatment further restrict the market growth. Several treatments for ascites, including diuretics and paracentesis, can lead to complications or side effects, such as electrolyte imbalances, infections, or low blood pressure. These potential risks may deter patients from seeking treatment or adhering to prescribed regimens, thus limiting the overall demand for these interventions. Additionally, the invasive nature of some treatments, such as the need for repeated paracentesis, can be uncomfortable for patients and may result in decreased willingness to pursue these conclusion, the global ascites market is expected to see steady growth, driven by the increasing prevalence of underlying conditions such as liver diseases and cancers, as well as advancements in diagnostic and therapeutic options. Continued research and innovation in targeted treatments, along with a growing focus on early detection, will be key to improving patient outcomes and reducing the burden of ascites on healthcare systems. As stakeholders, including pharmaceutical companies, healthcare providers, and researchers, continue to work toward better management strategies, the market will evolve to offer more effective solutions, ultimately enhancing the quality of life for patients and addressing the ongoing challenges posed by this Topics Covered: 1. Global Ascites Markets: Industry Outlook1.1 Introduction1.2 Market Trends1.3 Regulatory Framework1.4 Epidemiology of Ascites1.5 Clinical Trial Analysis1.6 Market Dynamics1.6.1 Impact Analysis1.6.2 Market Drivers1.6.3 Market Challenges1.6.4 Market Opportunities2. Global Ascites Market, by Region, $Million, 2023-20352.1 North America2.1.1 Key Findings2.1.2 Market Dynamics2.1.3 Market Sizing and Forecast2.1.3.1 North America Ascites Market, by Country2.1.3.1.1 U.S.2.2 Europe2.2.1 Key Findings2.2.2 Market Dynamics2.2.3 Market Sizing and Forecast2.2.3.1 Europe Ascites Market, by Country2.2.3.1.1 Germany2.2.3.1.2 U.K.2.2.3.1.3 France2.2.3.1.4 Italy2.2.3.1.5 Spain2.3 Asia Pacific2.3.1 Key Findings2.3.2 Market Dynamics2.3.3 Market Sizing and Forecast2.3.3.1 Asia Pacific Ascites Market, by Country2.3.3.1.1 Japan3. Global Ascites Market: Competitive Landscape and Company Profiles3.1 Key Development and Strategies3.1.1 Mergers and Acquisitions3.1.2 Synergistic Activities3.1.3 Business Expansions and Funding3.1.4 Product Launches and Approvals3.1.5 Other Activities3.2 Company Profiles3.2.1 Ocelot Bio3.2.1.1 Overview3.2.1.2 Top Products / Product Portfolio3.2.1.3 Target Customers/End-Users3.2.1.4 Key Personnel3.2.1.5 Analyst View3.2.2 PharmaIN3.2.3 Grifols Therapeutics LLC.3.2.4 Regeneron Pharmaceuticals.3.2.5 BioVie Inc4. Research Methodology For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
